OPTIMIZING STATIN THERAPY IN THE MANAGEMENT OF ISCHEMIC HEART DISEASE: A CLINICAL ASSESSMENT OF HIGH-INTENSITY REGIMENS AND ADHERENCE FACTORS

Ischemic heart disease (IHD) remains the leading cause of mortality in Uzbekistan, necessitating aggressive lipid-lowering strategies. Despite clear international guidelines, the utilization of high-intensity statin therapy remains suboptimal due to concerns regarding side effects and poor patient adherence. This article presents a prospective clinical study conducted at the Department of Cardiology of Andijan State Medical Institute. Using the IMRAD framework, the research evaluates the efficacy and safety of high-intensity Rosuvastatin therapy in patients with stable angina and post-myocardial infarction status. The study involved 200 patients randomized into a standard care group and an intensified education-monitoring group. The results demonstrate that patients receiving intensified support achieved guideline-directed LDL-cholesterol targets significantly more often (65 percent vs 30 percent) without a significant increase in hepatic or muscular adverse events. The study concludes that the primary barrier to effective statin therapy is not biological intolerance but rather psychosocial resistance, which can be overcome through targeted education and monitoring.缺血性心脏病（IHD）仍是乌兹别克斯坦居民的首要致死病因，因此亟需推行积极的降脂治疗策略。尽管已有明确的国际临床指南，但由于对不良反应的担忧以及患者依从性不佳，高强度他汀类药物治疗的临床应用仍未达最优水平。本文介绍了一项在安集延国立医学院心脏病学系开展的前瞻性临床研究。该研究遵循IMRAD研究框架展开，评估了高强度瑞舒伐他汀治疗方案对稳定型心绞痛及心肌梗死后患者的疗效与安全性。本研究共纳入200例患者，随机分为标准护理组与强化教育监测组。结果显示，接受强化支持干预的患者达成指南推荐的低密度脂蛋白胆固醇（LDL-cholesterol）控制目标的比例显著更高（65% vs 30%），且未出现肝脏或肌肉不良反应的显著增加。本研究得出结论：他汀类药物治疗未能实现理想效果的主要障碍并非生物学不耐受，而是社会心理层面的抗拒，此类抗拒可通过针对性教育与监测干预加以克服。